{"id":4433,"date":"2025-03-31T18:12:08","date_gmt":"2025-03-31T18:12:08","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/trifluoperazine-txt\/"},"modified":"2025-03-31T18:12:08","modified_gmt":"2025-03-31T18:12:08","slug":"trifluoperazine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/trifluoperazine-txt\/","title":{"rendered":"Trifluoperazine.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Schizophrenia and other psychoses Anxiety Severe nausea and vomiting

DOSE IN NORMAL RENAL FUNCTION <\/H3> Schizophrenia: initially 5 mg twice daily, increased by 5 mg after 1 week, then at intervals of 3 days according to response Anxiolytic and anti-emetic: 2\u20134 mg daily in divided doses; maximum 6 mg

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 407.5 <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : >99 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <1 <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp : 160 <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 22\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function. Start with low dose
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. Start with low dose
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Start with low dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp : Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with anti- arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide and amiodarone \u2013 avoid concomitant use with amiodarone\n
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant use\n
  • Antidepressants: increased level of tricyclics; possibly increased risk of antimuscarinic side effects\n
  • Anti-epileptics: antagonism (convulsive threshold lowered)\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: increased risk of ventricular arrhythmias with pimozide \u2013 avoid concomitant use\n
  • Antivirals: concentration possibly increased with ritonavir Anxiolytics and hypnotics: increased sedative effects\n
  • Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol\n
  • Diuretics: enhanced hypotensive effect\n
  • Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity\n
  • Pentamidine: increased risk of ventricular arrhythmias\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4> Oral

    Rate of Administration <\/H4> \u2013

    Comments<\/H4> \u2013

    OTHER INFORMATION <\/H4> Reduce starting dose in elderly or frail patients by at least half .
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Schizophrenia and other psychoses Anxiety Severe nausea and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4433","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4433"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4433\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}